WEBSITE BSE:539524 NSE: LALPATHLAB Inc. Year: 1995 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:59
No Notes Added Yet
1. Business Overview
Dr. Lal Pathlabs Ltd. is one of India's largest and most recognized diagnostic and related healthcare service providers. The company offers a comprehensive range of diagnostic tests, including routine and specialized pathology tests, molecular diagnostics, and basic radiology services. Its core business model involves collecting samples from patients (either at its collection centers, labs, or through home collection), processing these samples at its network of laboratories, and delivering accurate and timely reports. The company makes money by charging fees for these diagnostic tests and health packages. It serves individual patients, corporate clients, and refers from doctors and hospitals.
2. Key Segments / Revenue Mix
The primary revenue segment for Dr. Lal Pathlabs is pathology services, which includes a vast array of blood, urine, and other bodily fluid tests. Radiology services, while a smaller part of the business, are a growing segment. The revenue mix is diversified across walk-in patients, home collection services, doctor and hospital referrals, and corporate tie-ups. Geographically, the company has a strong presence in North and East India and is expanding its network across other regions, including West and South India. Specific percentage breakdowns for revenue segments are not publicly disclosed at a granular level.
3. Industry & Positioning
The Indian diagnostics industry is large and highly fragmented, comprising a mix of large organized players, regional chains, and numerous standalone labs. There is a discernible shift towards organized players due to their scale, advanced technology, quality accreditations, and brand trust. Dr. Lal Pathlabs is a leading organized diagnostic chain in India, holding a prominent position, especially in North India, where it has strong brand recall. It competes with other national chains like Metropolis Healthcare, SRL Diagnostics, Thyrocare Technologies, and Apollo Diagnostics, as well as hospital-attached labs and numerous unorganized players. The company is well-positioned to consolidate market share due to its established network and brand equity.
4. Competitive Advantage (Moat)
Dr. Lal Pathlabs benefits from several durable competitive advantages:
Brand & Trust: An established brand name with a long operating history (since 1949) instills high trust and perceived reliability among patients and doctors, which is crucial in healthcare.
Scale & Network: An extensive network of over 270 clinical labs and more than 5,000 patient service centers/collection centers across India provides a significant geographical reach and economies of scale in operations, procurement, and logistics.
Comprehensive Test Menu: Offers a wide array of over 4,000 routine and specialized tests, reducing the need for patients to seek multiple providers.
Quality & Accreditation: Investments in advanced technology, stringent quality controls, and national/international accreditations (NABL, CAP) ensure high accuracy and standardization, differentiating it from many smaller, unorganized labs.
5. Growth Drivers
Key factors expected to drive Dr. Lal Pathlabs' growth over the next 3-5 years include:
Increasing Healthcare Expenditure & Awareness: Rising disposable incomes, greater health consciousness, and increasing prevalence of lifestyle diseases are driving demand for diagnostic services.
Shift to Preventive Healthcare: Growing emphasis on early diagnosis, routine check-ups, and health packages.
Aging Population: An expanding elderly population leads to a higher incidence of chronic diseases requiring frequent diagnostic monitoring.
Market Consolidation: Continued shift from the unorganized to the organized sector, benefiting established players like Dr. Lal Pathlabs.
Geographic Expansion: Untapped potential in Tier 2 and Tier 3 cities, where the company is expanding its network.
Technological Advancements: Adoption of new diagnostic techniques and digital solutions (e.g., home collection apps, online reports) for enhanced convenience and efficiency.
6. Risks
Intense Competition & Price Wars: The fragmented nature of the industry and entry of new players could intensify pricing pressure, impacting margins.
Regulatory Changes: Healthcare is a highly regulated sector; changes in pricing caps, accreditation standards, data privacy laws, or other government policies could affect profitability and operations.
Reputational Risk: Any lapse in test accuracy, quality, or data security could severely damage brand trust and customer loyalty.
Technological Obsolescence: Rapid advancements in diagnostic technology necessitate continuous capital investment to remain competitive.
Talent Scarcity: Shortage of skilled pathologists and technicians could pose operational challenges and increase costs.
Economic Slowdown: A downturn in the economy could impact discretionary healthcare spending, including preventive check-ups.
7. Management & Ownership
Dr. Lal Pathlabs is a promoter-led company with a professional management team. It was founded by Dr. Maj. S.K. Lal in 1949 and is currently led by Dr. Om Prakash Lal (Chairman & Whole-time Director) and Dr. Vandana Lal (Whole-time Director), with Mr. Anjanesh Kumar Shah serving as CEO. The management team combines the vision of the founding family with professional expertise. Promoters hold a significant stake in the company, ensuring aligned long-term interests, alongside a diverse base of institutional investors (domestic and foreign) and public shareholders.
8. Outlook
Dr. Lal Pathlabs is well-positioned to capitalize on the long-term structural growth drivers of the Indian diagnostics market, including increasing healthcare awareness, rising incomes, and the shift towards organized, quality-focused diagnostic providers. Its strong brand, extensive network, and comprehensive test menu provide a significant competitive edge. However, the outlook is balanced by the inherent challenges of the highly fragmented and competitive industry, which could lead to periodic pricing pressures. The ability to sustain quality service standards across an expanding network while navigating regulatory changes and ongoing technological advancements will be crucial for maintaining its growth trajectory and profitability. Continued market share gains from the unorganized sector and successful penetration into underserved geographies are key to its future success.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹27598 Cr.
Stock P/E 56.1
P/B 11
Current Price ₹1646.3
Book Value ₹ 149.6
Face Value 10
52W High ₹1771.3
Dividend Yield 1.25%
52W Low ₹ 1272
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 539 | 545 | 602 | 660 | 597 | 603 | 670 | 731 | 660 | 703 |
| Other Income | 18 | 18 | 21 | 22 | 25 | 26 | 28 | 25 | 24 | 24 |
| Total Income | 557 | 564 | 623 | 682 | 622 | 628 | 698 | 755 | 684 | 727 |
| Total Expenditure | 398 | 401 | 432 | 458 | 443 | 434 | 478 | 507 | 481 | 516 |
| Operating Profit | 159 | 163 | 191 | 224 | 179 | 195 | 220 | 249 | 204 | 211 |
| Interest | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 7 | 6 |
| Depreciation | 36 | 37 | 35 | 35 | 36 | 36 | 35 | 41 | 42 | 45 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -30 | 0 |
| Profit Before Tax | 116 | 120 | 150 | 183 | 138 | 153 | 181 | 204 | 124 | 160 |
| Provision for Tax | 34 | 34 | 42 | 52 | 40 | -2 | 47 | 51 | 33 | 28 |
| Profit After Tax | 82 | 86 | 108 | 131 | 98 | 156 | 134 | 152 | 91 | 132 |
| Adjustments | -1 | -1 | -1 | -2 | -1 | -1 | -2 | -2 | -1 | -1 |
| Profit After Adjustments | 81 | 85 | 106 | 129 | 97 | 155 | 132 | 151 | 91 | 131 |
| Adjusted Earnings Per Share | 4.9 | 5.1 | 6.4 | 7.7 | 5.8 | 9.3 | 7.9 | 9 | 5.4 | 7.8 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 660 | 791 | 912 | 1057 | 1203 | 1330 | 1581 | 2087 | 2017 | 2227 | 2461 | 2764 |
| Other Income | 13 | 22 | 28 | 31 | 46 | 55 | 51 | 53 | 42 | 69 | 93 | 101 |
| Total Income | 673 | 813 | 940 | 1088 | 1249 | 1385 | 1633 | 2140 | 2059 | 2296 | 2555 | 2864 |
| Total Expenditure | 504 | 584 | 675 | 793 | 910 | 987 | 1145 | 1527 | 1527 | 1617 | 1766 | 1982 |
| Operating Profit | 168 | 229 | 265 | 295 | 340 | 399 | 488 | 613 | 532 | 678 | 789 | 884 |
| Interest | 0 | 0 | 1 | 1 | 1 | 15 | 16 | 30 | 38 | 29 | 22 | 23 |
| Depreciation | 28 | 28 | 28 | 33 | 38 | 73 | 77 | 108 | 150 | 144 | 142 | 163 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -30 |
| Profit Before Tax | 140 | 201 | 237 | 261 | 301 | 311 | 394 | 475 | 344 | 505 | 625 | 669 |
| Provision for Tax | 43 | 67 | 81 | 90 | 100 | 83 | 98 | 125 | 103 | 143 | 133 | 159 |
| Profit After Tax | 96 | 133 | 156 | 172 | 200 | 228 | 296 | 350 | 241 | 362 | 492 | 509 |
| Adjustments | -1 | -1 | -1 | -1 | -1 | -2 | -5 | -5 | -2 | -5 | -5 | -6 |
| Profit After Adjustments | 96 | 132 | 155 | 171 | 199 | 226 | 292 | 345 | 239 | 358 | 487 | 505 |
| Adjusted Earnings Per Share | 8.4 | 8 | 9.3 | 10.2 | 11.9 | 13.6 | 17.5 | 20.7 | 14.3 | 21.4 | 29.1 | 30.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 11% | 6% | 13% | 14% |
| Operating Profit CAGR | 16% | 9% | 15% | 17% |
| PAT CAGR | 36% | 12% | 17% | 18% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 18% | 19% | 3% | 13% |
| ROE Average | 25% | 21% | 23% | 26% |
| ROCE Average | 32% | 27% | 30% | 36% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 341 | 507 | 596 | 788 | 945 | 1033 | 1245 | 1502 | 1666 | 1849 | 2173 |
| Minority's Interest | 2 | 3 | 2 | 4 | 5 | 21 | 31 | 35 | 33 | 36 | 34 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 167 | 83 | 0 | 0 |
| Other Non-Current Liabilities | -5 | 12 | -6 | -9 | -20 | 70 | 83 | 106 | 93 | 62 | 21 |
| Total Current Liabilities | 112 | 91 | 85 | 116 | 138 | 227 | 274 | 500 | 470 | 464 | 402 |
| Total Liabilities | 450 | 613 | 676 | 899 | 1069 | 1351 | 1633 | 2310 | 2345 | 2411 | 2630 |
| Fixed Assets | 150 | 166 | 152 | 208 | 209 | 413 | 447 | 1369 | 1305 | 1194 | 1135 |
| Other Non-Current Assets | 18 | 24 | 57 | 68 | 47 | 46 | 41 | 66 | 67 | 91 | 132 |
| Total Current Assets | 282 | 424 | 467 | 623 | 814 | 893 | 1145 | 875 | 973 | 1127 | 1364 |
| Total Assets | 450 | 613 | 676 | 899 | 1069 | 1351 | 1633 | 2310 | 2345 | 2411 | 2630 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 16 | 23 | 27 | 29 | 66 | 129 | 197 | 244 | 378 | 264 | 361 |
| Cash Flow from Operating Activities | 122 | 159 | 171 | 197 | 219 | 284 | 398 | 447 | 456 | 535 | 569 |
| Cash Flow from Investing Activities | -113 | -163 | -137 | -172 | -100 | -26 | -212 | -449 | -287 | -24 | -303 |
| Cash Flow from Financing Activities | -1 | 0 | -32 | 13 | -55 | -190 | -139 | 136 | -283 | -414 | -334 |
| Net Cash Inflow / Outflow | 8 | -5 | 2 | 37 | 64 | 67 | 48 | 134 | -114 | 97 | -68 |
| Closing Cash & Cash Equivalent | 23 | 19 | 29 | 66 | 129 | 197 | 244 | 378 | 264 | 361 | 293 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 8.38 | 7.99 | 9.31 | 10.24 | 11.95 | 13.55 | 17.49 | 20.69 | 14.32 | 21.43 | 29.14 |
| CEPS(Rs) | 11.41 | 9.77 | 11.02 | 12.29 | 14.32 | 18.02 | 22.42 | 27.5 | 23.47 | 30.3 | 37.93 |
| DPS(Rs) | 0.77 | 1.23 | 1.5 | 2.25 | 3 | 6 | 10 | 6 | 6 | 12 | 12 |
| Book NAV/Share(Rs) | 28.78 | 30.64 | 35.33 | 46.19 | 55.04 | 59.99 | 72.31 | 86.59 | 96.44 | 107.7 | 126.57 |
| Core EBITDA Margin(%) | 23.52 | 26.24 | 26.03 | 24.98 | 24.4 | 25.83 | 27.59 | 26.86 | 24.29 | 27.36 | 28.26 |
| EBIT Margin(%) | 21.24 | 25.43 | 26.03 | 24.8 | 25.04 | 24.49 | 25.95 | 24.2 | 18.91 | 24.02 | 26.29 |
| Pre Tax Margin(%) | 21.18 | 25.36 | 25.96 | 24.72 | 24.97 | 23.34 | 24.94 | 22.75 | 17.05 | 22.7 | 25.38 |
| PAT Margin (%) | 14.62 | 16.84 | 17.05 | 16.25 | 16.66 | 17.11 | 18.75 | 16.78 | 11.95 | 16.27 | 20 |
| Cash Profit Margin (%) | 18.89 | 20.41 | 20.07 | 19.38 | 19.83 | 22.58 | 23.63 | 21.96 | 19.4 | 22.72 | 25.76 |
| ROA(%) | 24.67 | 25.06 | 24.13 | 21.81 | 20.38 | 18.81 | 19.87 | 17.77 | 10.36 | 15.23 | 19.53 |
| ROE(%) | 37.14 | 32.45 | 28.45 | 25.32 | 23.76 | 23.74 | 26.89 | 26.45 | 15.8 | 21.27 | 25.15 |
| ROCE(%) | 48.87 | 47.43 | 43.07 | 37.9 | 34.78 | 32.94 | 36.03 | 32.67 | 20.34 | 27.89 | 31.53 |
| Receivable days | 15.53 | 15.51 | 15.62 | 14.32 | 14.31 | 14.35 | 13.63 | 13.3 | 14.14 | 12.15 | 12.27 |
| Inventory Days | 7.18 | 6.64 | 6.49 | 7.81 | 8.47 | 11.73 | 11.49 | 8.31 | 7.81 | 5.83 | 5.45 |
| Payable days | 87.86 | 80.66 | 87.64 | 95.14 | 101.04 | 120.69 | 120.3 | 105.92 | 123.86 | 138.53 | 146.09 |
| PER(x) | 0 | 57.63 | 51.99 | 42.7 | 44.12 | 51.69 | 77.38 | 63.02 | 63.8 | 52.8 | 42.52 |
| Price/Book(x) | 0 | 15.04 | 13.69 | 9.47 | 9.58 | 11.68 | 18.72 | 15.06 | 9.48 | 10.5 | 9.79 |
| Dividend Yield(%) | 0 | 0.27 | 0.31 | 0.51 | 0.57 | 0.86 | 0.74 | 0.46 | 0.66 | 1.06 | 0.97 |
| EV/Net Sales(x) | -0.1 | 9.36 | 8.55 | 6.6 | 6.9 | 8.35 | 13.68 | 10.28 | 7.34 | 8.15 | 8.08 |
| EV/Core EBITDA(x) | -0.4 | 32.28 | 29.42 | 23.63 | 24.43 | 27.87 | 44.38 | 34.99 | 27.86 | 26.74 | 25.19 |
| Net Sales Growth(%) | 18.22 | 19.97 | 15.3 | 15.84 | 13.86 | 10.55 | 18.86 | 32.01 | -3.38 | 10.4 | 10.54 |
| EBIT Growth(%) | 17.35 | 43.6 | 18.04 | 10.37 | 14.96 | 8.11 | 25.96 | 23.09 | -24.51 | 40.24 | 21 |
| PAT Growth(%) | 20.15 | 38.15 | 16.78 | 10.39 | 16.72 | 13.53 | 30.27 | 18.15 | -31.18 | 50.28 | 35.87 |
| EPS Growth(%) | 17.26 | -4.64 | 16.4 | 10.09 | 16.65 | 13.43 | 29.07 | 18.25 | -30.75 | 49.58 | 35.99 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.24 | 0.15 | 0.05 | 0 |
| Current Ratio(x) | 2.52 | 4.67 | 5.5 | 5.37 | 5.88 | 3.93 | 4.18 | 1.75 | 2.07 | 2.43 | 3.39 |
| Quick Ratio(x) | 2.39 | 4.51 | 5.29 | 5.14 | 5.68 | 3.68 | 4.02 | 1.65 | 2 | 2.35 | 3.3 |
| Interest Cover(x) | 346.2 | 404.57 | 340.29 | 311.72 | 359.22 | 21.28 | 25.65 | 16.74 | 10.16 | 18.22 | 29.01 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 54.6 | 54.6 | 54.6 | 53.92 | 53.91 | 53.91 | 53.79 | 53.21 | 53.21 | 53.21 |
| FII | 25.35 | 26.15 | 25.42 | 26.82 | 26.82 | 23.91 | 21.68 | 21.86 | 20.29 | 17.18 |
| DII | 9.56 | 9.69 | 12.71 | 12.89 | 13.17 | 16.08 | 17.79 | 18.34 | 19.07 | 21.25 |
| Public | 10.49 | 9.56 | 7.26 | 6.37 | 6.11 | 6.1 | 6.74 | 6.58 | 7.43 | 8.36 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.56 | 4.56 | 4.56 | 4.51 | 4.51 | 4.51 | 4.51 | 4.46 | 8.92 | 8.92 |
| FII | 2.12 | 2.18 | 2.12 | 2.24 | 2.24 | 2 | 1.82 | 1.83 | 3.4 | 2.88 |
| DII | 0.8 | 0.81 | 1.06 | 1.08 | 1.1 | 1.34 | 1.49 | 1.54 | 3.2 | 3.56 |
| Public | 0.88 | 0.8 | 0.61 | 0.53 | 0.51 | 0.51 | 0.56 | 0.55 | 1.24 | 1.4 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8.35 | 8.35 | 8.35 | 8.36 | 8.36 | 8.36 | 8.38 | 8.38 | 16.76 | 16.76 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.